Chapter 39. Evidence-Based Treatment of Burkitt Lymphoma in Adults

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. John Gerecitano MD, PhD and
  2. David J. Straus MD

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch39

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Gerecitano, J. and Straus, D. J. (2009) Evidence-Based Treatment of Burkitt Lymphoma in Adults, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch39

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Lymphoma Service, Department of Medicine, Memorial Sloan–Kettering Cancer Center, New York, New York, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • Burkitt lymphoma in adults;
  • optimal therapy for adult patients;
  • diffuse large B-cell lymphoma (DLBCL);
  • acute lymphoblastic leukemia (ALL);
  • CODOX-M/IVAC for adult patients with Burkitt lymphoma;
  • recombinant urate oxidase as tumor lysis syndrome prophylaxis/treatment in Burkitt lymphoma;
  • hyperuricemia prevention with xanthine oxidase inhibitor use;
  • Rasburicase - recombinant form of urate oxidase

Summary

This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusion

  • Is there a role for surgical “Debulking” in Burkitt lymphoma?

  • What is the optimal therapy for adult patients?

  • Is the outcome of treatment worse for patients with Burkitt lymphoma associated with HIV infection than those without HIV infection?

  • What is the role of recombinant urate oxidase as tumor lysis syndrome prophylaxis/treatment in Burkitt lymphoma?

  • Recommendation

  • References